|
|
|
 |
FDA Approval Activities for this Drug…
Precose (acarbose) Tablets, Bayer NDA 20-482/S-011 10/29/02 11/18/02 | Precose (acarbose) Tablets, Bayer NDA 20-482/S-010 8/16/99 5/19/00 | Precose (acarbose) Tablets, Bayer Pharmaceutical Division NDA 20-482/S-007 and S-008 9/29/98 9/29/98 12/11/98 | Precose Indications: S-007- provided for the new combination use of Precose for patients with type 2 diabetes treated with diet plus insulin; and S-008- provided for the new combination of Precose for patients with type 2 diabetes with diet and metformin. | Precose (acarbose) Tablets, Bayer Pharma, Labeling Revision | Acarbose Tablets, Roxane Laboratories, Inc., Approval | Acarbose Tablets, Cobalt Laboratories, Approval | Precose (acarbose) Tablets, Bayer HealthCare Pharmaceuticals, Labeling Revision | Acarbose Tablets, IMPAX Laboratories, Inc., Approval | Acarbose Tablets, Mylan Pharmaceuticals, Inc., Approval | Precose (acarbose) Tablets, Bayer HealthCare Pharmaceuticals, Labeling Revision | Acarbose Tablets, Strides Arcolab, Ltd., Approval
  
|